# Nanologica > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/nanologica). ## Overview Nanologica is a Swedish life-science company that develops and manufactures porous silica materials used in preparative chromatography. Its products are designed for purification steps in pharmaceutical production, especially for peptide drugs such as insulin and GLP-1 therapies, and the company also provides application support and method development. ## Products & services • NLAB Saga® silica-based purification media • NLAB® Idun ion-exchange chromatography media • Preparative chromatography materials for peptide purification • Application support and method development • Customized chromatography products - **Silica-based purification media** (70%) — Porous silica materials used in preparative chromatography for pharmaceutical purification. - **Ion-exchange chromatography media** (15%) — Complementary purification media for peptide drug separation and polishing steps. - **Application support and method development** (10%) — Technical support to help customers evaluate, optimize and implement the media. - **Customized chromatography solutions** (5%) — Tailored products and process support for specific customer purification workflows. - NLAB Saga® silica-based purification media - NLAB® Idun ion-exchange chromatography media - Preparative chromatography materials for peptide purification - Application support and method development - Customized chromatography products ## Customers Nanologica sells primarily to pharmaceutical companies and contract manufacturers that produce insulin, insulin analogues, GLP-1 analogues, biosimilars and other peptide drugs. These customers buy the company’s silica media because it helps them purify target molecules efficiently at industrial scale and improve manufacturing workflows. The sales process is technical and evaluation-driven, with customers typically testing the material before moving toward larger production use. - **Pharmaceutical manufacturers** (primary) — Buy purification media for insulin, GLP-1 and other peptide-drug production because they need high-quality, scalable chromatography inputs. - **Contract development and manufacturing organizations (CDMOs)** (primary) — Use the media in outsourced production workflows where purification performance, reliability and scale matter. - **Biosimilar producers** (secondary) — Evaluate the media for purification of biosimilar insulin and related peptide products as they scale manufacturing. - **Process development teams** (secondary) — Purchase small evaluation quantities and technical support to validate fit before production-scale adoption. - Pharmaceutical manufacturers of insulin and insulin analogues - GLP-1 drug producers and peptide-drug developers - Contract manufacturers serving pharma customers - Biosimilar producers evaluating purification performance - Customers seeking technical support for process optimization ## Geography Nanologica sells through a sales organization that covers major markets, with dedicated coverage for India, China, the United States and Europe. The company’s revenue is exposed to foreign exchange movements because a large share of sales is denominated in USD while many costs are in GBP and SEK. Its customer base is global, but commercial traction is especially tied to pharmaceutical manufacturing hubs in North America, Europe and Asia. - Sales coverage includes India, China, the United States and Europe - Revenue is largely USD-denominated, creating FX exposure - Costs include a meaningful GBP component from production and suppliers - Customer demand follows global peptide-drug manufacturing hubs - Geographic diversification matters for commercialization and scale ## Strategy Nanologica’s strategy is to build a scalable business around high-performance silica media for peptide-drug purification, with a focus on insulin and obesity-related therapies. The company is prioritizing commercialization, production and technology development, while broadening its product portfolio and deepening customer partnerships. - **Commercialize NLAB Saga®** (short-term) — The core growth opportunity depends on converting customer evaluations into production-scale adoption. - **Broaden the chromatography portfolio** (medium-term) — Complementary products increase the addressable market and improve customer retention. - **Scale production and technical capability** (medium-term) — Reliable supply and consistent product quality are essential for industrial pharmaceutical customers. - Commercialize NLAB Saga® across global pharma customers - Expand the portfolio with complementary media such as NLAB® Idun - Strengthen production capability and manufacturing scalability - Provide application support to improve customer adoption - Build partnerships with pharmaceutical manufacturers worldwide ## Risks Nanologica faces financing, commercialization and execution risks typical of an early commercial-stage life-science supplier. Its customers demand high product quality, delivery reliability and extensive validation, while competition and differing test methods can make adoption uncertain; the business is also exposed to currency swings, supplier dependence and key-person risk. - **Capital raising dependence** [critical] — If the company cannot secure funding, development, manufacturing and sales activities may be limited or suspended. - **Commercialization risk** [high] — Revenue depends on converting technical evaluations into repeat production orders, which can take 3-18 months. - **Product performance and customer testing risk** [high] — Different customers use different methods and conditions, so products may perform differently in trials. - **Manufacturing and supply-chain risk** [high] — Production relies on contract manufacturers, raw materials and specialized equipment, creating delay and quality risk. - **Foreign exchange risk** [medium] — A large share of revenue is in USD while costs are partly in GBP, so exchange-rate moves affect results. - **Key-person dependence** [medium] — The company is small and depends heavily on specialized management and technical staff. - Need for external capital can constrain operations and growth - Customer qualification cycles are long and technically demanding - Product performance can vary across customer test methods - Manufacturing disruptions or supplier failures can delay deliveries - FX exposure is meaningful because revenue and costs are in different currencies ## Accounting The most important accounting judgments relate to inventory valuation, manufacturing cost allocation and lease accounting. Because products are produced in stages and partly through contract manufacturers, inventory and cost of sales depend on standard-cost assumptions, overhead allocation and write-downs for slow-moving or obsolete materials; the company also recognizes right-of-use assets and lease liabilities for premises and embedded equipment leases under IFRS 16. - **Inventory valuation and write-downs** — affects cost of sales, inventory and operating profit - **Manufacturing cost allocation** — affects inventory carrying values and gross margin - **Lease accounting under IFRS 16** — affects balance sheet and operating expense presentation - **Loss carryforwards** — affects deferred tax assets and equity - Inventory valuation depends on cost, FIFO and net realizable value - Standard-cost assumptions affect manufacturing cost and gross margin - Onerous or obsolete inventory may require write-downs - IFRS 16 lease accounting affects assets, liabilities and depreciation - Loss carryforwards are not recognized as deferred tax assets --- *Last updated: 2026-08-11T04:04:54.711828+00:00*